Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.40
Bid: 22.00
Ask: 24.00
Change: 0.00 (0.00%)
Spread: 2.00 (9.091%)
Open: 24.00
High: 24.40
Low: 24.00
Prev. Close: 23.00
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oncimmune Starts Trading On AIM As Motorpoint Shares Stay Firm (ALLIPO)

Wed, 18th May 2016 08:46

LONDON (Alliance News) - Oncimmune Holdings PLC shares slipped on their debut on London's AIM market on Wednesday, as unconditional dealings also started in Motorpoint Group PLC shares.

Oncimmune, an early cancer detection technology company, raised GBP11.0 million through the issue of shares at 130.00 pence per share. Its market capitalisation upon admission was around GBP66.3 million.

Shares in the company edged down in early dealings though, to 129.00p.

Oncimmune intends to use proceeds from the float to continue to develop its products, focused on auto-antibody tests which it said have the potential to detect cancer up to four years earlier than other methods, and can be applied to a "very wide range" of solid tumour types.

Meanwhile, unconditional dealings started on the London Main Market in shares of car dealer Motorpoint Group PLC. It floated last week, raising GBP100.0 million and starting life as a listed company with a GBP200.0 million market capitalisation.

Motorpoint shares were trading at 225.00p on Wednesday, 13% ahead of its 200.00p float price.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
10 May 2019 12:59

Oncimmune begins study to bring 'EarlyCDT-Lung' to China

(Sharecast News) - Oncimmune Holdings, alongside its partner Genostics Company, announced the start of a multi-centre case control study on early lung cancer detection for screening and nodules in the People's Republic of China on Friday, using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.

Read more
10 May 2019 11:36

Oncimmune And Genostics Initiate Trial Of EarlyCDT-Lung In China

LONDON (Alliance News) - Oncimmune Holdings PLC and Genostics Co Ltd on Friday said a multi-centre case control study on early lung cancer detection in China has started.The company said is

Read more
5 Apr 2019 15:10

Oncimmune inks distribution deal for lung cancer test in Portugal

(Sharecast News) - Personalised immunodiagnostics developer Oncimmune Holdings has signed an exclusive agreement for the distribution of its 'EarlyCDT-Lung' test kit in Portugal with Sabartech, its existing distributor in Spain, it announced on Friday.

Read more
5 Apr 2019 10:04

Oncimmune Signs Lung Cancer Test Kit Distribution Deal With Sabartech

LONDON (Alliance News) - Cancer diagnostics company Oncimmune Holdings PLC on Friday said it has signed an exclusive agreement for the distribution of its lung cancer test kit in Portgual with can

Read more
2 Apr 2019 10:50

Oncimmune strengthens scientific board with addition of Parag Mallick

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the appointment of Dr Parag Mallick - an associate professor of radiology at Stanford University - to its scientific board on Tuesday.

Read more
19 Mar 2019 12:19

Oncimmune Buys Protagen Diagnostics In EUR4 Million All-Share Deal (ALLISS)

LONDON (Alliance News) - Cancer testing firm Oncimmune Holdings PLC said Tuesday it acquired protein biomarker laboratory Protagen Diagnostics AG for EUR4.1 million in an all-share will buy the of

Read more
19 Mar 2019 09:10

Oncimmune acquires Protagen Diagnostics in £4.11m deal

(Sharecast News) - Oncimmune Holdings has acquired Protagen Diagnostics for a total consideration of up to £4.11m, it announced on Tuesday, to be paid by the allotment of up to 2,635,910 Oncimmune ordinary shares at 156p each 0 a premium of 71% to the closing mid-market price on 18 March.

Read more
13 Feb 2019 10:45

Oncimmune Loss Widens In First Half On Administrative Costs

LONDON (Alliance News) - Cancer diagnostics business Oncimmune Holdings PLC on Wednesday said its loss widened in the first half its year on higher administrative expenses.In the six months

Read more
13 Feb 2019 09:20

Oncimmune Holdings' loss deepens on spiralling costs

(Sharecast News) - Oncimmune Holdings reported a widened interim loss on Wednesday as increases to research & development costs and administrative costs outweighed a rise in revenue.

Read more
20 Dec 2018 16:27

Oncimmune buoyed by US distribution deal for blood tests

(Sharecast News) - Oncimmune Holdings made gains on Thursday after it entered an agreement with America's Choice Provider Network to expand access to its EarlyCDT-Lung and EarlyCDT-Liver blood tests.

Read more
6 Dec 2018 17:39

Oncimmune Appoints Former Tusk Therapeutics CFO Matthew Hall To Board

LONDON (Alliance News) - Cancer diagnostics firm Oncimmune Holdings PLC on Thursday said its has appointed former Tusk Therapeutics Ltd Chief Financial Officer Matthew Hall as finance will replace

Read more
28 Nov 2018 11:57

Oncimmune signs sales deals in multiple countries for 'EarlyCDT-Lung' test

(Sharecast News) - Immunodiagnostics developer Oncimmune Holdings has signed exclusive agreements for the distribution of its 'EarlyCDT-Lung' test in Germany with hrmed.tech, in France with Eurobio Scientific, and in Italy with BSN, it announced on Wednesday.

Read more
31 Oct 2018 09:19

Oncimmune Annual Loss Deepens As Costs Hurt, Chases Cancer Test Deals

LONDON (Alliance News) - Oncimmune Holdings PLC said Wednesday its full year loss deepened on higher costs as it continues to chase new distribution deals for its cancer detection blood test the a

Read more
1 Oct 2018 12:47

Oncimmune inks multiple new distribution agreements

(Sharecast News) - Oncimmune revealed on Monday that it had signed multiple new distribution agreements for its EarlyCDT-Lung test as part of an early morning trading update.

Read more
25 Sep 2018 17:21

Oncimmune Says Lung Cancer Blood Test Outperforms Risk Calculator

LONDON (Alliance News) - Pharma company Oncimmune Holdings PLC on Tuesday said its lung cancer blood test, EarlyCDT-Lung, has proven to be more effective than a standard risk produced a positive a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.